Plan your next move right from the start

Edwards SAPIEN platform: The choice for lifetime management

Plan your next move right from the start

Edwards SAPIEN platform: The choice for lifetime management

The PARTNER 3 trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year1
  • Time: The only transcatheter heart valve with 90% survival at 5 years6
  • Management: The only transcatheter heart valve with a THV-in-THV indication5*
Visit NEJM to download View the clinical publication

*For patients assessed at high-risk for surgical replacement.

Consistently demonstrating the results you need for the outcomes that matter1

With patients of all ages living longer and having high expectations for their quality of life, lifetime management is increasingly important.2

The first valve choice matters.

From outstanding outcomes and excellent durability* today to facilitating future interventions tomorrow, the SAPIEN platform is designed to deliver a TAVI experience an implanter can count on.3,4

*Propensity matched analysis of intermediate risk patients using VARC-3 definitions of SVD and SVD related BVF at 5 years.

New York Valves 2024

SAPIEN 3 TAVR: a therapy with durable outcomes through 5 years, including for small annulus and female patients

5-year data shows excellent clinical outcomes and durability for small annulus and female patients with SAPIEN 3 TAVR

An analysis of more than 1,300 low and intermediate risk patients followed out to 5 years treated with the SAPIEN 3 Platform
Excellent clinical outcomes, low rates of reintervention, and sustained quality of life improvement through five years
Download the presentation

Watch Dr. Hahn’s Late Breaking Clinical Trials & Science presentation from New York Valves 2024

Watch video

Recorded Live at ACC24:*

Contemporary results of TAVR with balloon expandable valves including results in small annuli and durability

Hear from your peers about the outcomes that can make an impact on a successful lifetime management strategy for all patients.

Contemporary results with the SAPIEN 3 Ultra RESILIA valve

Clinical outcomes of balloon expandable valves in small annuli: the latest data

Durability: what does the patient care about?

TAVR Results in Small Annuli Patients: Early Reactions to New Data

Coffee Talk at ACC 2024 with Dr. Vinod Thourani and Dr. Philippe Généreux

*Edwards sponsored symposium at ACC in Atlanta, Georgia on April 7, 2024.

Outcomes

Consistent outcomes that matter, starting with the index procedure.1

Explore outcomes ›

Durability

A comprehensive approach to a durable therapy that offers proven long-term patient outcomes.3,6

Explore durability ›

Future Interventions

Making future options possible.4,5

Explore future options ›

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVI experience an implanter can count on, starting with the index procedure.

View the brochure

References:

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
2. Life expectancy continued to decrease in 2021 in the EU. Eurostat website. Published May 6, 2022. Accessed August 9, 2023. https://ec.europa.eu/eurostat/en/web/products-eurostat-news/-/ddn-20220506-2.
3. Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in PARTNER-2 trial. J Am Coll Cardiol. 2020;76(16):1830-1843.
4. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.
5. Tarantini G, et al. Redo-Transcatheter aortic valve implantation using the SAPIEN 3/Ultra transcatheter heart valves – Expert Consensus on Procedural Planning Techniques, The American Journal of Cardiology, 2023.
6. Mack MJ, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N Engl J Med. 2023 Nov 23;389(21):1949-1960.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER 3, RESILIA, the PARTNER design logo, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

PP--EU-6941 v4.0